{"id":"perioperative-folfox","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of these drugs works synergistically to inhibit thymidylate synthase, interfere with DNA replication, and induce DNA damage, ultimately leading to cell death. Oxaliplatin also causes DNA damage through the formation of platinum-DNA adducts.","oneSentence":"FOLFOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:32.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colon cancer"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05855200","phase":"PHASE3","title":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"Colonic Neoplasms, Neoplasms, Colon","enrollment":892},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06031285","phase":"PHASE2","title":"Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT02572141","phase":"PHASE3","title":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2015-01-01","conditions":"Colon Cancer","enrollment":738},{"nctId":"NCT06296563","phase":"PHASE2","title":"Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC","status":"RECRUITING","sponsor":"Lei ZHAO","startDate":"2024-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20},{"nctId":"NCT05986227","phase":"PHASE1, PHASE2","title":"The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-08-01","conditions":"Gastroesophageal Adenocarcinoma","enrollment":126},{"nctId":"NCT05519410","phase":"PHASE2","title":"Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-08-23","conditions":"Resectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT04889820","phase":"NA","title":"Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Catholic University of Korea","startDate":"2021-11-01","conditions":"Colon Cancer, Obstruction","enrollment":204},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT03985891","phase":"PHASE1, PHASE2","title":"The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-12-16","conditions":"Colonic Neoplasms, Chemotherapy Effect","enrollment":40},{"nctId":"NCT03961841","phase":"PHASE3","title":"Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-06","conditions":"Esophagogastric Junction Disorder, Neoplasms","enrollment":900},{"nctId":"NCT01260415","phase":"PHASE2","title":"A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-08","conditions":"Colorectal Cancer, Liver Metastases","enrollment":11},{"nctId":"NCT02486601","phase":"PHASE2","title":"NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2015-06","conditions":"Cancer of Stomach","enrollment":55},{"nctId":"NCT01646554","phase":"PHASE2, PHASE3","title":"Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-12","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer","enrollment":""},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT01364376","phase":"NA","title":"S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2011-06","conditions":"Stomach Neoplasms","enrollment":583},{"nctId":"NCT01675999","phase":"PHASE2","title":"Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-05","conditions":"Colon Cancer, Locally Advanced Malignant Neoplasm","enrollment":186},{"nctId":"NCT01266187","phase":"NA","title":"Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-07","conditions":"Liver Metastasis","enrollment":16},{"nctId":"NCT01540435","phase":"PHASE2","title":"Perioperative Treatment of Resectable Liver Metastases","status":"WITHDRAWN","sponsor":"University of Regensburg","startDate":"2012-09","conditions":"Colon Cancer Liver Metastasis","enrollment":""},{"nctId":"NCT00438737","phase":"PHASE2","title":"Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Perioperative FOLFOX","genericName":"Perioperative FOLFOX","companyName":"Sixth Affiliated Hospital, Sun Yat-sen University","companyId":"sixth-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}